Return On Equity of Theravance Biopharma, Inc. from 30 Sep 2014 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Theravance Biopharma, Inc. quarterly and annual Return On Equity in % history and change rate from 30 Sep 2014 to 30 Sep 2025.
  • Theravance Biopharma, Inc. Return On Equity for the quarter ending 30 Sep 2025 was 15%.
  • Theravance Biopharma, Inc. annual Return On Equity for 2024 was -30%, a 49% decline from 2023.
  • Theravance Biopharma, Inc. annual Return On Equity for 2023 was -20%, a 101% decline from 2022.
  • Theravance Biopharma, Inc. annual Return On Equity for 2022 was 1578%, a 2542% increase from 2021.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Change (%)
Return On Equity, Annual (%)
Return On Equity, YoY Annual Change (%)

Theravance Biopharma, Inc. Quarterly Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
Q3 2025 15% +39% 01 Jul 2025 30 Sep 2025
Q2 2025 6.9% +28% 01 Apr 2025 30 Jun 2025
Q1 2025 -32% -13% -71% 01 Jan 2025 31 Mar 2025
Q4 2024 -30% -9.8% -49% 01 Oct 2024 31 Dec 2024
Q3 2024 -25% -7.7% -45% 01 Jul 2024 30 Sep 2024
Q2 2024 -21% -242% -110% 01 Apr 2024 30 Jun 2024
Q1 2024 -19% -390% -105% 01 Jan 2024 31 Mar 2024
Q4 2023 -20% -1598% -101% 01 Oct 2023 31 Dec 2023
Q3 2023 -17% +591% +97% 01 Jul 2023 30 Sep 2023
Q2 2023 221% +191% +642% 01 Apr 2023 30 Jun 2023
Q1 2023 372% +327% +738% 01 Jan 2023 31 Mar 2023
Q4 2022 1578% +1518% +2542% 01 Oct 2022 31 Dec 2022
Q3 2022 -608% -678% -976% 01 Jul 2022 30 Sep 2022
Q2 2022 30% -56% -65% 01 Apr 2022 30 Jun 2022
Q1 2022 44% -52% -54% 01 Jan 2022 31 Mar 2022
Q4 2021 60% -60% -50% 01 Oct 2021 31 Dec 2021
Q3 2021 69% -65% -49% 01 Jul 2021 30 Sep 2021
Q2 2021 85% -56% -39% 01 Apr 2021 30 Jun 2021
Q1 2021 96% -44% -32% 01 Jan 2021 31 Mar 2021
Q4 2020 120% -24% -17% 01 Oct 2020 31 Dec 2020
Q3 2020 135% -47% -26% 01 Jul 2020 30 Sep 2020
Q2 2020 141% -141% -50% 01 Apr 2020 30 Jun 2020
Q1 2020 141% -479% -77% 01 Jan 2020 31 Mar 2020
Q4 2019 144% +2775% 01 Oct 2019 31 Dec 2019
Q3 2019 182% +688% 01 Jul 2019 30 Sep 2019
Q2 2019 282% +543% 01 Apr 2019 30 Jun 2019
Q1 2019 620% +809% 01 Jan 2019 31 Mar 2019
Q4 2018 -2632% -2495% -1823% 01 Oct 2018 31 Dec 2018
Q3 2018 -506% -406% -409% 01 Jul 2018 30 Sep 2018
Q2 2018 -262% -183% -232% 01 Apr 2018 30 Jun 2018
Q1 2018 -189% -121% -179% 01 Jan 2018 31 Mar 2018
Q4 2017 -137% -74% -117% 01 Oct 2017 31 Dec 2017
Q3 2017 -99% -38% -63% 01 Jul 2017 30 Sep 2017
Q2 2017 -79% -8% -11% 01 Apr 2017 30 Jun 2017
Q1 2017 -68% +8% +11% 01 Jan 2017 31 Mar 2017
Q4 2016 -63% +8.9% +12% 01 Oct 2016 31 Dec 2016
Q3 2016 -61% +15% +20% 01 Jul 2016 30 Sep 2016
Q2 2016 -71% +0.24% +0.34% 01 Apr 2016 30 Jun 2016
Q1 2016 -76% -8.3% -12% 01 Jan 2016 31 Mar 2016
Q4 2015 -72% +23% +24% 01 Oct 2015 31 Dec 2015
Q3 2015 -76% +50% +39% 01 Jul 2015 30 Sep 2015
Q2 2015 -71% 01 Apr 2015 30 Jun 2015
Q1 2015 -67% 01 Jan 2015 31 Mar 2015
Q4 2014 -95% 01 Oct 2014 31 Dec 2014
Q3 2014 -126% 01 Jul 2014 30 Sep 2014

Theravance Biopharma, Inc. Annual Return On Equity (%)

Period Value YoY Chg Change % Start Date End Date
2024 -30% -9.8% -49% 01 Jan 2024 31 Dec 2024
2023 -20% -1598% -101% 01 Jan 2023 31 Dec 2023
2022 1578% +1518% +2542% 01 Jan 2022 31 Dec 2022
2021 60% -60% -50% 01 Jan 2021 31 Dec 2021
2020 120% -24% -17% 01 Jan 2020 31 Dec 2020
2019 144% +2775% 01 Jan 2019 31 Dec 2019
2018 -2632% -2495% -1823% 01 Jan 2018 31 Dec 2018
2017 -137% -74% -117% 01 Jan 2017 31 Dec 2017
2016 -63% +8.9% +12% 01 Jan 2016 31 Dec 2016
2015 -72% +23% +24% 01 Jan 2015 31 Dec 2015
2014 -95% 01 Jan 2014 31 Dec 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.